Top

Published in:

01-03-2009 | Original Article

Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation

Authors: Baijun Fang, Yongping Song, Ning Li, Jing Li, Qin Han, Robert Chunhua Zhao

Published in: Annals of Hematology | Issue 3/2009

Abstract

Pure red cell aplasia (PRCA) is a well-known, although infrequent, hematological complication after allogeneic hematopoietic stem cell transplantation (HSCT). PRCA occurs in cases of major ABO mismatch between donor and recipient and is believed to be due to inhibition of donor erythroid progenitors by residual host isohemagglutinins. The purpose of our study was to further evaluate the efficacy of human adipose tissue-derived mesenchymal stem cells (AMSC) as the salvage therapy for refractory PRCA after major ABO-incompatible HSCT. Two patients with refractory pure red cell aplasia received intravenous infusions of AMSC at a dose of 1.5 × 10⁶/kg of the patients’ weight, and rapid recovery from PRCA without any side effects was observed. We conclude that AMSC seems to be a promising therapeutic option in patients with PRCA after ABO-mismatched HSCT, in whom conventional treatment fails.

Worel N, Kalhs P, Keil F, Prinz E, Moser K, Schulenburg A et al (2003) ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. Transfusion 43:1153–1161 doi:10.1046/j.1537-2995.2003.00465.x PubMedCrossRef

Lee JH, Lee KH, Kim S, Lee JS, Kim SH, Kwon SW et al (2000) Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant 25:179–184 doi:10.1038/sj.bmt.1702121 PubMedCrossRef

Gmür JP, Burger J, Schaffner A, Neftel K, Oelz O, Frey D et al (1990) Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood 75:290–295PubMed

Lee JH, Lee JH, Choi SJ, Kim S, Seol M, Kwon SW et al (2002) Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. Br J Haematol 120:702–710 doi:10.1046/j.1365-2141.2003.04128.x CrossRef

Badros A, Tricot G, Toor A, Morris C, Guo C, Munshi N et al (2002) ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion 42:205–209 doi:10.1046/j.1537-2995.2002.00027.x PubMedCrossRef

Mielcarek M, Leisenring W, Torok-Storb B, Storb R (2000) Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood 96:1150–1156PubMed

Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M et al (1991) Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med 325:1267–1273PubMed

Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F et al (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107:367–372 doi:10.1182/blood-2005-07-2657 PubMedCrossRef

Han Q, Liao L, You S, Deng H, Zhao RC (2005) Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol 24:458–463 doi:10.1089/dna.2005.24.574 PubMedCrossRef

10.

Fang B, Song Y, Zhao RC, Han Q, Cao Y (2007) Treatment of resistant pure red cell aplasia after major ABO-incompatible bone marrow transplantation with human adipose tissue-derived mesenchymal stem cells. Am J Hematol 82:772–773 doi:10.1002/ajh.20932 PubMedCrossRef

11.

Cao Y, Sun Z, Liao L, Meng Y, Han Q, Zhao RC (2005) Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. Biochem Biophys Res Commun 332:370–379 doi:10.1016/j.bbrc.2005.05.034 PubMedCrossRef

12.

Deng W, Han Q, Liao L, Li C, Ge W, Zhao Z et al (2005) Engrafted bone marrow-derived flk-(1+) mesenchymal stem cells regenerate skin tissue. Tissue Eng 11:110–119 doi:10.1089/ten.2005.11.110 PubMedCrossRef

13.

Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringdén O (2003) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57:11–20 doi:10.1046/j.1365-3083.2003.01176.x PubMedCrossRef

14.

Martelli M, Ponchio L, Beguin Y, Meloni G, Mandelli F, Cazzola M (1994) Pure red cell aplasia following peripheral stem cell transplantation: complete response to a short course of high-dose recombinant human erythropoietin. Haematologica 79:456–459PubMed

15.

Ohashi K, Akiyama H, Takamoto S, Tanikawa S, Sakamaki H, Onozawa Y (1994) Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation resistant to erythropoietin. Bone Marrow Transplantation Team. Bone Marrow Transplant 13:335–336PubMed

16.

Veelken H, Wäsch R, Behringer D, Bertz H, Finke J (2000) Pure red cell aplasia after allogeneic stem cell transplantation with reduced conditioning. Bone Marrow Transplant 26:911–915 doi:10.1038/sj.bmt.1702629 PubMedCrossRef

17.

Sahovic EA, Flick J, Graham CD, Stuart RK (1991) Case report: isoimmune inhibition of erythropoiesis following ABO-incompatible bone marrow transplantation. Am J Med Sci 302:369–373 doi:10.1097/00000441-199112000-00009 PubMedCrossRef

18.

Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI et al (2000) Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 18:307–316PubMed

19.

Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI (1995) Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 16:557–564PubMed

20.

Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M et al (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439–1441 doi:10.1016/S0140-6736(04)16104-7 PubMedCrossRef

21.

Fang B, Song Y, Lin Q, Zhang Y, Cao Y, Zhao RC et al (2007) Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children. Pediatr Transplant 11:814–817 doi:10.1111/j.1399-3046.2007.00780.x PubMedCrossRef

22.

Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J et al (2007) Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21:1733–1738 doi:10.1038/sj.leu.2404777 PubMedCrossRef

23.

Fang B, Song Y, Liao L, Zhang Y, Zhao RC (2007) Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc 39:3358–3362 doi:10.1016/j.transproceed.2007.08.103 PubMedCrossRef

24.

Fang B, Song YP, Liao LM, Han Q, Zhao RC (2006) Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells. Bone Marrow Transplant 38(5):389–390 doi:10.1038/sj.bmt.1705457 PubMedCrossRef

25.

Verholen F, Stalder M, Helg C, Chalandon Y (2004) Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. Eur J Haematol 73:441–446 doi:10.1111/j.1600-0609.2004.00320.x PubMedCrossRef

Title: Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation
Authors: Baijun Fang
Yongping Song
Ning Li
Jing Li
Qin Han
Robert Chunhua Zhao
Publication date: 01-03-2009
Publisher: Springer-Verlag
Published in: Annals of Hematology / Issue 3/2009
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-008-0599-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

A limited number of 5-azacitidine cycles can be effective treatment in MDS

Novel missense mutation c.2685G>C (p.Q895H) in VWF gene associated with very low levels of VWF mRNA

Non-classical hereditary hemochromatosis in Portugal: novel mutations identified in iron metabolism-related genes

Thrombotic thrombocytopenic purpura in the first trimester and successful pregnancy

Haemoglobinopathies with high oxygen affinity. Experience of Erythropathology Cooperative Spanish Group

Complete cytogenetic remission after decitabine treatment in a patient with secondary AML harbouring high p15 INK4b gene methylation and high global DNA methylation

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials